Extavia (IFN-β-1b) / Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Extavia (IFN-β-1b) / Novartis
TERIVA, NCT01403376 / 2011-001160-21: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Completed
2
128
Canada, Europe, RoW
teriflunomide, HMR1726, Interferon-β-1, Rebif®, Avonex®, Betaseron®, Betaferon®, Extavia®, Genfaxone®, Influenza vaccine
Sanofi
Multiple Sclerosis
01/12
01/12
2010-023677-19: Bio-molecular effects of interferon-beta and d-vitamin association

Ongoing
2
15
Europe
BETAFERON*15CONFEZ 0,25MG/ML+, EXTAVIA*SC 15FL 250MCG/ML+15SI, DIBASE, BETAFERON*15CONFEZ 0,25MG/ML+, EXTAVIA*SC 15FL 250MCG/ML+15SI, DIBASE
AZIENDA OSPEDALIERA S. LUIGI GONZAGA
PATIENT WITH RRMS AND SPMS
 
 
2020-001892-34: Treatment of COVID-19 by Nebulization of Inteferon Beta 1b added to lopinavir/ritonavir: Feasibility, Efficiency and Safety Study Traitement du COVID-19 : Etude de faisabilité, d’efficacité et de sécurité de l’ajout de Nébubilisation d’Interferon Beta 1b au lopinavir/ritonavir

Not yet recruiting
2
60
Europe
Inteferon Beta 1b, lopinavir/ritonavir, NaCl, Powder and solvent for solution for injection, Coated tablet, Solution for injection, Extavia, Lopinavir/Ritonavir Mylan, NaCl
CHU Amiens-Picardie, CHU Amiens
Infection SARS-Cov-2 Infection SARS-Cov-2, covid 19 covid 19, Diseases [C] - Virus Diseases [C02]
 
 
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24

Download Options